+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diarrhea - Pipeline Review, H1 2019

  • ID: 4758513
  • Drug Pipelines
  • 140 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Albireo Pharma Inc
  • AzurRx BioPharma Inc
  • DiscoveryBiomed Inc
  • MyBiotics Pharma Ltd
  • Novartis AG
  • RedHill Biopharma Ltd
  • MORE
Diarrhea - Pipeline Review, H1 2019

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H1 2019, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights:

This latest pipeline guide Diarrhea - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 9, 6, 17 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 5 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Albireo Pharma Inc
  • AzurRx BioPharma Inc
  • DiscoveryBiomed Inc
  • MyBiotics Pharma Ltd
  • Novartis AG
  • RedHill Biopharma Ltd
  • MORE
Introduction

Diarrhea - Overview

Diarrhea - Therapeutics Development

Diarrhea - Therapeutics Assessment

Diarrhea - Companies Involved in Therapeutics Development

Diarrhea - Drug Profiles

Diarrhea - Dormant Projects

Diarrhea - Discontinued Products

Diarrhea - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Diarrhea, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Diarrhea - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2019

Diarrhea - Pipeline by Albireo Pharma Inc, H1 2019

Diarrhea - Pipeline by Allergan Plc, H1 2019

Diarrhea - Pipeline by Ardelyx Inc, H1 2019

Diarrhea - Pipeline by AzurRx BioPharma Inc, H1 2019

Diarrhea - Pipeline by Bharat Biotech Ltd, H1 2019

Diarrhea - Pipeline by Boston Pharmaceuticals Inc, H1 2019

Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2019

Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H1 2019

Diarrhea - Pipeline by DiscoveryBiomed Inc, H1 2019

Diarrhea - Pipeline by Ferring International Center SA, H1 2019

Diarrhea - Pipeline by GP Pharm SA, H1 2019

Diarrhea - Pipeline by Kaleido Biosciences Inc, H1 2019

Diarrhea - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2019

Diarrhea - Pipeline by MyBiotics Pharma Ltd, H1 2019

Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H1 2019

Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H1 2019

Diarrhea - Pipeline by Novartis AG, H1 2019

Diarrhea - Pipeline by Prokarium Ltd, H1 2019

Diarrhea - Pipeline by Protagonist Therapeutics Inc, H1 2019

Diarrhea - Pipeline by RaQualia Pharma Inc, H1 2019

Diarrhea - Pipeline by RedHill Biopharma Ltd, H1 2019

Diarrhea - Pipeline by RxBio Inc, H1 2019

Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H1 2019

Diarrhea - Pipeline by Synthetic Biologics Inc, H1 2019

Diarrhea - Pipeline by Syntiron LLC, H1 2019

Diarrhea - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2019

Diarrhea - Pipeline by VenatoRx Pharmaceuticals Inc, H1 2019

Diarrhea - Pipeline by Zealand Pharma AS, H1 2019

Diarrhea - Dormant Projects, H1 2019

Diarrhea - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Diarrhea, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Akthelia Pharmaceuticals Ltd
  • Albireo Pharma Inc
  • Allergan Plc
  • Ardelyx Inc
  • AzurRx BioPharma Inc
  • Bharat Biotech Ltd
  • Boston Pharmaceuticals Inc
  • Chongqing Zhifei Biological Products Co Ltd
  • Cosmo Pharmaceuticals NV
  • DiscoveryBiomed Inc
  • Ferring International Center SA
  • GP Pharm SA
  • Kaleido Biosciences Inc
  • Kuhnil Pharmaceutical Co Ltd
  • MyBiotics Pharma Ltd
  • Napo Pharmaceuticals Inc
  • Nippon Shinyaku Co Ltd
  • Novartis AG
  • Prokarium Ltd
  • Protagonist Therapeutics Inc
  • RaQualia Pharma Inc
  • RedHill Biopharma Ltd
  • RxBio Inc
  • Scandinavian Biopharma Holding AB
  • Synthetic Biologics Inc
  • Syntiron LLC
  • Tasly Pharmaceutical Group Co Ltd
  • VenatoRx Pharmaceuticals Inc
  • Zealand Pharma AS
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4758513
Adroll
adroll